Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial) / Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, Gl; Galligioni, E. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 30:5(2012), pp. 120-120. [10.1200/jco.2012.30.5_suppl.220]

Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial)

Buti S;
2012

Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial) / Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, Gl; Galligioni, E. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 30:5(2012), pp. 120-120. [10.1200/jco.2012.30.5_suppl.220]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906910
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact